| Edition |
First edition. |
| Description |
xxiv, 482 pages ; 24 cm |
|
text txt rdacontent |
|
unmediated n rdamedia |
|
volume nc rdacarrier |
|
Gender group: gdr Women lcdgt |
|
Nationality/regional group: nat New Yorkers (New York State) lcdgt |
|
Occupational/field of activity group: occ Journalists lcdgt |
| Bibliography |
Includes bibliographical references (pages [421]-461) and index. |
| Contents |
Shifting Ground. The man who saw further -- The gold rush -- A slum for the rich -- The language of quality -- Red flags -- India Rises. Freedom fighters -- One dollar a day -- A clever way of doing things -- The assignment -- A Cat-and-Mouse Business. The global cover-up -- Map of the world -- The pharaoh of pharma -- Making a Case. Out of the shadows -- "Do not give to FDA" -- "How big is the problem?" -- Diamond and ruby -- "You just don't get it" -- Detectives in the Dark. Congress wakes up -- Solving for X -- A test of endurance -- A deep, dark well -- The $600 million jacket -- The Watershed. The light switch -- We are the champions -- Crashing files -- The ultimate testing laboratory -- Reckonings. Flies too numerous to count -- Standing. |
| Summary |
"Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban's Bottle of Lies exposes the deceit behind generic-drug manufacturing--and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings?"--Dust jacket. |
| Subject |
Generic drugs -- Quality control.
|
|
Drug adulteration.
|
|
Pharmaceutical industry -- Corrupt practices -- United States.
|
|
Drugs, Generic -- standards. (DNLM)D016568Q000592 |
|
Fraud. (DNLM)D005607 |
|
Drug Industry -- standards. (DNLM)D004345Q000592 |
|
Drug Industry -- legislation & jurisprudence. (DNLM)D004345Q000331 |
|
Government Regulation. (DNLM)D033161 |
|
Drug Contamination -- legislation & jurisprudence. (DNLM)D004340Q000331 |
|
Pharmaceutical industry -- Corrupt practices.
(OCoLC)fst01060133
|
|
Drug adulteration. (OCoLC)fst00898652
|
|
United States. (OCoLC)fst01204155
|
|
Generic drugs.
|
| Genre/Form |
Informational works. (OCoLC)fst01919930
|
|
Informational works.
|
| Added Title |
Inside story of the generic drug boom |
| ISBN |
9780062338785 (hardback) |
|
0062338781 (hardback) |
|
9780062338792 |
|
006233879X |
|
9780062917645 |
|
0062917641 |
|
9780062917652 |
|
006291765X |
|
